Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study
Barbara A. Conley, Lou Staudt, Naoko Takebe, et al.
JNCI Journal of the National Cancer Institute (2020) Vol. 113, Iss. 1, pp. 27-37
Open Access | Times Cited: 25

Showing 25 citing articles:

TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
Jayakumar Vadakekolathu, Catherine Lai, Stephen Reeder, et al.
Blood Advances (2020) Vol. 4, Iss. 20, pp. 5011-5024
Open Access | Times Cited: 122
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment
David A. Wheeler, Naoko Takebe, Toshinori Hinoue, et al.
Cancer Cell (2020) Vol. 39, Iss. 1, pp. 38-53.e7
Open Access | Times Cited: 89
Exceptional responses to systemic treatment in metastatic breast cancer: clinical features and long-term outcomes
Gaia Griguolo, Michele Bottosso, A Crema, et al.
European Journal of Cancer (2025) Vol. 219, pp. 115321-115321
Open Access | Times Cited: 1
Long-term survival and undetectable circulating tumor DNA following comprehensive involved site radiotherapy for oligometastases
Rachel Radigan, Chinghai Kao, Michael Krainock, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Anastasis and Other Apoptosis-Related Prosurvival Pathways Call for a Paradigm Shift in Oncology: Significance of Deintensification in Treating Solid Tumors
Razmik Mirzayans
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 1881-1881
Open Access
Functional Precision Medicine: Putting Drugs on Patient Cancer Cells and Seeing What Happens
Anthony Letai
Cancer Discovery (2022) Vol. 12, Iss. 2, pp. 290-292
Open Access | Times Cited: 15
Expanding the scope, reach, and impact of evidence-based psychological treatments
Alan E. Kazdin
Journal of Behavior Therapy and Experimental Psychiatry (2022) Vol. 76, pp. 101744-101744
Closed Access | Times Cited: 9
Tumor Profiling at the Service of Cancer Therapy
Ceres Fernández‐Rozadilla, Ana Rita Simões, Matilde E. Lleonart, et al.
Frontiers in Oncology (2021) Vol. 10
Open Access | Times Cited: 11
Comprehensive analysis for clarifying transcriptomics landscapes of spread through air spaces in lung adenocarcinoma
Yuan Zeng, Lingli Zhou, Dexin Jia, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 7
Polygenic risk scores for autoimmune related diseases are significantly different in cancer exceptional responders
Siyuan Chen, Amelia L.M. Tan, Maria Clara Saad Menezes, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 1
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations
Alessandro Di Federico, Stefania Angelicola, Mariateresa Frascino, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 1
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single‐arm, phase 2 study
James J. Harding, Tsai‐Sheng Yang, Yen‐Yang Chen, et al.
Cancer (2021) Vol. 127, Iss. 24, pp. 4585-4593
Open Access | Times Cited: 9
A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC): In-Depth Analysis of Nintendanib Arm from the KCSG HN 15-16 TRIUMPH Trial
Kyoo Hyun Kim, Sun Min Lim, Hee Kyung Ahn, et al.
Cancer Research and Treatment (2023)
Open Access | Times Cited: 3
Understanding resistance to immune checkpoint inhibitors in advanced breast cancer
Paolo Tarantino, Romualdo Barroso‐Sousa, Ana C. Garrido-Castro, et al.
Expert Review of Anticancer Therapy (2021) Vol. 22, Iss. 2, pp. 141-153
Closed Access | Times Cited: 7
From N-of-one to series of exceptional responders: unlocking the mystery of outliers in oncology
Julieta Rodriguez, Santiago Ponce-Aix
ESMO Open (2023) Vol. 8, Iss. 5, pp. 101833-101833
Open Access | Times Cited: 2
How to discover the exceptional venetoclax responders in AML/MDS?
Bjørn Tore Gjertsen
British Journal of Haematology (2023) Vol. 204, Iss. 1, pp. 14-15
Open Access | Times Cited: 2
Commentary on the prescient observations made by Emil J Freireich in Effectiveness of platelet transfusion in leukemia and aplastic anemia (Transfusion 1966; 6: 50–54)
Charles A. Schiffer
Transfusion (2022) Vol. 62, Iss. 2, pp. 267-272
Closed Access | Times Cited: 3
Circulating tumor DNA (ctDNA) as a new and evolving tool in solid organ transplantation
Pashtoon Murtaza Kasi
Elsevier eBooks (2024), pp. 175-180
Closed Access
Exceptional toxicity resistance
Stephen T. Sonis, Alessandro Villa, Joel B. Epstein
Supportive Care in Cancer (2021) Vol. 29, Iss. 5, pp. 2263-2264
Open Access | Times Cited: 2
Editorial: Case reports in gastrointestinal cancers : 2022
Pashtoon Murtaza Kasi
Frontiers in Oncology (2023) Vol. 13
Open Access
One Step Further Toward Defining the Exceptional Cancer Responder
James M. Ford, Beverly S. Mitchell
JNCI Journal of the National Cancer Institute (2020) Vol. 113, Iss. 1, pp. 3-4
Open Access
Biomarker Panels and Contemporary Practice in Clinical Trials of Personalized Medicine
Nina Louise Jebsen, Irini Ktoridou-Valen, Bjørn Tore Gjertsen
Springer eBooks (2022), pp. 549-562
Closed Access
Survey of Lifestyle, Past Medical History and Complementary and Alternative Medicine Use Among Adult Patients Participating in the National Cancer Institute's Exceptional Responders Initiative
Oluwadamilola Olaku, Barbara A. Conley, S. Percy Ivy, et al.
Translational Oncology (2022) Vol. 25, pp. 101484-101484
Open Access
Are there markers for exceptional responders available for attending pathologists
Haruhiko Sugimura
临床与病理杂志 (2021) Vol. 39, Iss. 10
Closed Access
Exceptional Responders in Gynecologic Oncology: A case series and review of literature
Pallavi Verma, Amrita Gaurav, Sandipan Choudhuri, et al.
Indian Journal of Gynecologic Oncology (2021) Vol. 19, Iss. 4
Closed Access
Page 1

Scroll to top